Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer
Anti-Inflammatory Drug Fails In A Third Setting
Executive Summary
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.